Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis

Sirio Fiorino, Maria Letizia Bacchi-Reggiani, Paolo Leandri, Elisabetta Loggi, Pietro Andreone

Abstract

AIM
To assess vitamin E efficacy, defined as its ability to induce hepatitis B e antigen (HBeAg) seroconversion, in children with HBeAg-positive persistent hepatitis.

METHODS
In July 2016, we extracted articles published in MEDLINE and the Cochrane Library using the following search terms: “chronic hepatitis B”, “children”, “childhood”, “therapy”, “treatment”, “vitamin E”, “tocopherols”, “tocotrienols”. Only randomized controlled trials (RCTs) published in English language were collected.

RESULTS
Three RCTs met inclusion criteria and were considered in the present meta-analysis. Overall, 23/122 children in the treatment group underwent HBeAg seroconversion vs 3/74 in the control group (OR = 3.96, 95%CI: 1.18-13.25, \(P = 0.025\)).

CONCLUSION
Although our meta-analysis has several limits, including the very small number of available studies and enrolled children with HBeAg positivity-related hepatitis, it suggests that vitamin E use may enhance the probability to...
Treatment of chronic hepatitis B in children

**Key words:** Hepatitis B; Pediatric hepatology; Viral hepatitis; Immunology

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Treatment of chronic hepatitis B in children is still an area of uncertainty. Vitamin E, based on immunostimulatory anti-inflammatory activity, has been evaluated in the treatment of pediatric hepatitis B virus infection. These few experiences seem to be encouraging as they suggest a potential role of vitamin E in inducing HBeAg seroconversion, but they need to be confirmed in well-designed and adequately sized trials.

Fiorino S, Bacchi-Reggiani ML, Leandri P, Loggi E, Andreone P. Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis. World J Hepatol 2017; 9(6): 333-342 Available from: URL: http://www.wjgnet.com/1948-5182/full/v9/i6/333.htm DOI: http://dx.doi.org/10.4254/wjh.v9.i6.333

INTRODUCTION

Chronic hepatitis B virus (HBV) infection continues to represent a very serious health problem worldwide, both in adults and in children[1], despite several efforts to prevent its spread and to reduce its disease burden, such as vaccination programs[2], the use of safe injection techniques and blood donor screening[3], as well as the introduction, in our therapeutic arsenal, of new and more advanced and effective antiviral treatments[4]. The clinical relevance of this pathogen depends on its ability to insidiously induce, in a large proportion of infected individuals, a necro-inflammatory hepatic disease with different patterns of severity and course, including cirrhosis and hepatocellular carcinoma. Several factors have been demonstrated to influence the prevalence[5], severity and outcome of patients with HBV-related chronic hepatitis. In particular, ethnicity, mode of acquisition and mainly, age at the time of HBV infection represent the major risk factors for the development of a persistent liver disease[6]. Whereas approximately 90%-95% of acutely HBV-infected immunocompetent adults experience a self-limiting hepatitis with the establishment of protective long-lasting immunity, and only the remaining 5%-10% develop chronic hepatitis, neonatal transmission of HBV causes a higher rate of chronic infection[7]. Approximately 90% of infected children in highly endemic countries, where vertical transmission from mother to child is predominant, become persistent carriers[8]. According to the current knowledge, the natural history of long-lasting HBV infection is characterized by three chronological phases, including immune tolerance, immune clearance and low replication status.

Despite a large series of available studies, long-term outcomes of HBV infection acquired in infancy are still unclear. However, the spontaneous or therapy-induced hepatitis B e antigen (HBeAg) seroconversion with HBe antibody development is generally considered a key event in patients with long-lasting HBV-related infection[9], because it is often accompanied by remission of liver disease and confers a favorable course over a long-term follow-up[10]. After HBeAg loss, serum HBsAg persists, but serum aminotransferase levels usually decrease, reaching normal or low values and a significant reduction in HBV replication is observed in a large part of the subjects undergoing HBeAb development[11]. Nevertheless, in some of these patients, the achievement of HBeAg seroconversion is not associated with the improvement of hepatic disease, rather these individuals still present with liver damage with different grades of severity and course and they are at higher risk of developing complications later in life[12]. Persistent HBV-related infection is considered as the result of an impaired immune response against this pathogen, consequently the boosting of antiviral immune response has become an innovative strategy in the attempt to obtain the remission of the infection, which still occurs at very low rate[13,14]. Starting from this assumption, a randomized controlled pilot trial was performed in 2001 in adult patients with HBV-related hepatitis, showing beneficial effects in anti-viral activities in these individuals[15].

Therefore, on the basis of these findings, we aimed to perform a systematic review and meta-analysis to identify and summarize the current evidence on the potential efficacy of vitamin E in the treatment of children with HBeAg-positive persistent hepatitis, defined as its ability to induce HBeAg loss and HBeAb development.

MATERIALS AND METHODS

Search strategy

A systematic computer-based search of published articles, according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis Statement, issued in 2009[16], was conducted through Ovid interface, in order to identify relevant studies on the vitamin E use for the treatment of children with HBeAg-positive chronic hepatitis. The literature review was performed in July 2016. The following electronic databases were used: MEDLINE (1950 to June 30, 2016), the Cochrane Library (until the second quarter of 2016) and EMBASE (1980 to June 30, 2016) for all relevant articles. The search strategy and the search terms were developed with the support of a professional research librarian. The text word used for the search were identified by means of controlled vocabulary, such as the National Library of Medicine's MESH (Medical Subject Headings) and Keywords. The used MESH terms and keywords were: "chronic hepatitis B", "children", "childhood", "therapy", "treatment", "vitamin E", "tocopherols", "tocotrienols". The PubMed "related articles"
feature as well as the reference lists of retrieved articles was also searched to find additional pertinent studies. If a study was considered potentially eligible by either of the two reviewers, the full-text of this study was further evaluated. Full-text assessment was performed according to eligibility criteria developed to systematically include studies into this review. Selected studies were considered eligible if all the following predefined criteria were met: (1) the research was designed to assess the tolerability and efficacy of vitamin E use for the treatment of children with HBV-seropositive chronic hepatitis; (2) the research studies were designed as randomized studies; (3) the studies were reported in the English language, as peer-reviewed, full-text publications, whereas articles that were not published as full reports, such as conference abstracts, case reports, and editorials were excluded; and (4) sufficient data for the evaluation of HBV seroconversion rate were available (Table 1).

**Study selection**

Data extraction: Two authors (Leandri P and Loggi E), independently and in a parallel manner, performed the literature search, identified and screened relevant articles, based on title or title and abstract. If a study was considered potentially eligible by either of the 2 reviewers, the full article was collected for further assessment. Other two authors (Bacchi-Reggiani ML and Andreone P) independently extracted and tabulated all relevant data from included studies by means of a standardized method, according to the Cochrane handbook section 7.3a checklist of domains. The following information was obtained from each study, by means of a predefined data extraction form, including: First author's name, study design, inclusion and exclusion criteria, year of publication, country of origin, ethnicity, number of cases and controls, diagnostic methods for HBV markers and genome detection. We contacted the authors of the three studies to obtain additional information, including children's seroconversion rate by age groups and by HBV-genotype. Unfortunately, access to patients' database was possible only for one study, whereas the above mentioned data, concerning the other two trials, were no longer available for the time period elapsed since their publication. The accuracy of data collection was checked by SF, and any disagreements concerning the results were settled by consensus between all authors.

**Quality score assessment:** Three investigators (Fiorino S, Bacchi-Reggiani ML and Andreone P) independently evaluated the quality of the selected studies, on the basis of the Jadad scale[17] (Table 2). It includes the assessment of the following three items: Randomization (2 points as maximum score), blinding (2 points as maximum score) and an account for all patients (1 point as maximum score).

Any disagreement was resolved by discussion with the other authors. Total score ranges from 0 to 5. Included studies were classified into higher quality (≥3) and lower quality (<3), on the basis of the total scores.

**Statistical analysis**

Odds ratios (ORs) and 95% confidence intervals (CIs) were used as the summary statistic. The pooled OR was calculated with both fixed effect (inverse variance weighting) and random effect (Der Simonian and Laird) models. To avoid the exclusion of one among the eligible studies[18], a 0.5 zero-cell correction was used. The variability, expressed in percentage across studies and attributable to heterogeneity beyond chance, was estimated with $I^2$ statistic. We assessed the extent of small study effects by Egger's test. P-values $\leq 0.05$ were considered significant for all included studies. Statistical analyses were carried out using STATA/SE version 14.1 (STATA Corp., College Station, TX, United States).

**RESULTS**

**Study selection**

We searched in MEDLINE, EMBASE, and Cochrane Library to retrieve works assessing vitamin E use in children with HBV-seropositive chronic hepatitis. Our systematic review identified 2471 potential studies, and 2458 of them were excluded after a preliminary review of the titles and/or abstracts. The full texts of the remaining 13 articles were retrieved for a more detailed assessment. Of these, 10 studies did not meet the eligibility criteria, as described, because they were reviews, clinical studies carried out in adults or they were not published in the English language. Therefore, three studies were selected and included in the current meta-analysis. A flow-chart of the study search and selection process is shown in Figure 1.

**Study characteristics**

Three randomized controlled studies, assessing the use of tocopherols in children with HBV-related chronic infection and rate of HBV seroconversion, met inclusion criteria and were considered in the present meta-analysis[18–20].

Overall, the three trials involved 122 children, randomized to receive treatment according to an intention-to-treat protocol with different doses of vitamin E, and 74 controls. One study was performed in Turkey, one in Germany and one in Italy. The baseline characteristics of these included studies and their participants are summarized in Table 1. All considered studies described serological assays, which were employed to detect viral infection markers. Serum samples were tested for the presence of both viral antigens and host antiviral antibodies, using both enzyme-linked immunosorbent assay and radioimmunoassay, as well as of HBV-DNA, by means of liquid hybridization or real time PCR[19,20].

Overall, according to the Jadad scale, two trials were classified into higher quality[19,20] and one into lower quality[18] studies (Table 1).

The end-point of this meta-analysis was to estimate the potential antiviral efficacy of vitamin E, defined as its...
| First author/year | Study design/country of origin | Sample size | Treat and VE dose | Treat period/follow-up | End-points | Main results | Quality score | Tolerability |
|-------------------|-------------------------------|-------------|------------------|------------------------|------------|-------------|---------------|-------------|
| Dickici B, 2007   | PRT (1:1) Turkey              | 58          | 100 mg/d vs no treatment | 3 mo/6 mo              | HBV-DNA clearance HBeAg seroconversion | No antiviral-effects induced by vitamin E treatment | 1            | No side effects |
|                   |                               | (1) 30 treated patients M/F: 21/9 (2) Age (yr): (9.0 ± 3.8) | No data concerning age 28 untreated patients M/F: 23/5 Age (yr): (8.5 ± 4.5) No data available for children’s seroconversion rates by age groups and by HBV genotype |
| Gerner P, 2008    | PRT (3:1) Germany             | 92          | From 200 to 600 IU/d depending on body weight vs placebo | 6 mo/12 mo             | HBV-DNA clearance HBeAg loss HBeAg seroconversion | VE may induce HBeAg seroconversion, but further studies are required | 5            | Well-tolerated Self-limited gastroenteritis cases |
|                   |                               | (1) 69 in treatment group (2) 23 in placebo group | 76 children completed the study (1) 56 in treatment group M/F: 34/22 Age (yr): 10.4 (2) 20 in placebo group M/F: 12/8 Age (yr): 11.8 No data available for children’s seroconversion rates by age groups and by HBV genotype |
| Fiorino S, 2016   | PRT (1:1) Italy               | 46          | 15 mg/kg per day vs no treatment | 12 mo/12 mo | (1) safety and tolerability (2) HBsAg loss/anti-HBs seroconversion (3) efficacy of VE in inducing: (1) ≥ 2 log₁₀ sustained decrease in serum HBV-DNA vs baseline | VE may induce HBeAg seroconversion, but further studies are required | 3            | Generally good safety profile Self-limited gastroenteritis (nausea, vomiting, upper abdominal pain, diarrhoea), headache, fatigue Adverse events: ALT flare |
|                   |                               | (1) 23 in treatment group (18 in immune-tolerant phase and 5 in immune-reactive group) (2) 23 in placebo group (17 in immune-tolerant phase and 6 in immune-reactive group) | 40 children completed the study |
|                   |                               | (1) 20 in treatment group M/F: 15/5 Age (yr): (11.9 ± 3.8) (2) 20 in placebo group M/F: 16/4 Age (yr): (10.2 ± 3.5) HBeAg seroconversion in vitamin E Age (yr)/number pts/ genotype 2/0 3/0 4/1 (F1) 5/0 6/2 (1A, 1D) |
ability to induce HBeAg loss and HBeAb development. A pooled estimate was performed on the basis of the considered studies. Overall, we observed that vitamin E use induced HBeAg seroconversion in 18.8% patients (23 seroconversion among 122 patients in the treated children vs 3 among 74 controls, OR = 3.96, 95%CI: 1.18-13.25, P = 0.025, I² = 0.0%) (Figure 2). Children’s seroconversion rates by age groups and by HBV genotype were available only for one of the three trials (Table 1).

**Sensitivity analysis and publication bias risk**
To evaluate the effect of each individual study on the overall meta-analysis estimate, one study at a time was excluded, but the exclusion of any single research did not cause a significant alteration of the final decision and did not suggest the possibility of publication bias, but the number of considered studies is very small and this factor suggests caution in data interpretation.

**DISCUSSION**
The natural history of HBV-related persistent infection in childhood as well as the indications for the appropriate use of the antiviral therapy still represent an area of considerable uncertainty in this subset of patients, although an expert panel consensus[21] and some meta-analyses[22,23] have been proposed to guide physicians in the treatment decision-making process. As no definitive guidelines exist, according to available recommendations, the criteria for the management of these subjects in the real-life clinical setting have to be carefully evaluated before initiating any type of antiviral therapy. In particular, treatment is considered appropriate in HBeAg-positive children with persistently elevated (about 1.5-2.0 times the laboratory upper limit of normal), or exceeding 60 IU/L serum alanine aminotransferase and moderate/severe inflammation/fibrosis on liver biopsy[8]. Some drugs, such as interferon-α (IFN-α)[24], lamivudine[25], entecavir[26], adefovir[27] and tenofovir[28] have been approved for these patients. However, their use is limited by important side effects, risk of resistance development, high costs and, mainly, age of the treated subjects[29]. Most of these antiviral compounds have been licensed for children over 12 years old and only IFN-α as well as entecavir have been approved for a pediatric population aged between 2 and 18 years[24,26]. In addition, to date, no therapy is considered appropriate in HBeAg-positive children in the immune tolerance phase. A risk of resistance development to antiviral drugs exists in this group of patients[21]. To date, on the basis of these results, a long-term follow-up is the only approach currently applied to these children and further therapeutic approaches or treatment schedules are required[30]. Therefore, according to preliminary observations on the beneficial role of vitamin E as therapy in patients with chronic hepatitis B in a randomized controlled pilot

| Age (yr)/number pts/ genotype | 7/0 | 8/3 (1C, 2D) | 9/0 | 10/2 (1C, 1D) | 11/0 | 12/1 (1D) | 13/6 (1A, 1C, 4D) | 14/3 (1A, 1D, 1NA) | 15/0 | 16/2 (1D, 1F) | 17/5 (3D) |
|------------------------------|-----|-------------|-----|--------------|------|-----------|-----------------|-------------------|------|-------------|-----------|
| HBeAg seroconversion in the control group | | | | | | | | | | | |
| Age (yr)/number pts/ genotype | 2/1 (B) | 3/0 | 4/1 (D) | 5/1 (A) | 6/1 (D) | 7/0 | 8/3 (1C, 2E) | 9/1 (D) | 10/1 (C) | 11/5 (1A, 2C, 2D) | 12/2 (1A, 1E) | 13/2 (1B, 1D) | 14/4 (2A, 2NA) | 15/1 (D) | 16/0 | 17/0 |

1Identifies 1 patients undergoing HBeAb seroconversion in a subgroup of patients; 2Identifies 2 patients, who underwent HBeAg seroconversion; 3According to the Jadad scale. PRT: Prospective randomized trial; IT: Immune-tolerant; IR: immune-reactive; VE: Vitamin E; CVR: Complete virological response, defined as sustained HBeAg loss/anti-HBe seroconversion together with serum HBV-DNA reduction < 2000 IU/mL; ALT: Alanine-aminotransferase; NA: Not available; HBeAg: Hepatitis B e antigen; M: Male; F: Female.

---

Fiorino S et al. Vitamin E in pediatric hepatitis B infection
A recent research performed by Chan et al,[31] using TDF (tenofovir disoproxil fumarate) or TDF + FTC (emtricitabine) in adult immune-tolerant patients, showed low percentage of HBcAg loss and HBsAg development (5% and 0% respectively) over 192 wk. The reasons explaining these high seroconversion rates in children supplemented with vitamin E in contrast to subjects treated with TDF analogs, mainly in Fiorino’s study, are not completely understood and deserve further investigations. Nevertheless, some very interesting issues have to be considered: (1) different mechanisms of vitamin E and nucleotidic/nucleosidic analogue action; (2) duration of the treatment period; and (3) vitamin E dosage used.

Nucleos(t)ide analogues exert antiviral activities by means of well-known direct as well as indirect mechanisms: (1) suppression of HBV replication mainly through the inhibition of reverse transcription process in the viral lifecycle[32]; (2) partial restoration of the impaired immune response, as shown by significant reductions in the percentages of CD4⁺CD25⁺[33] T regulatory cells, programmed death-ligand 1 (PD-L1) receptor expression on CD4⁺ T cells and pro-inflammatory cytokine production[34]. Therefore, antigen-viral burden reduction is associated with the improvement of anti-HBV activity of immune cells. According to our current knowledge, vitamin E exerts its beneficial effects by means of similar mechanisms. It is well known that vitamin E plays critical roles for normal cellular functions[35]. This essential liposoluble compound, acting as a free radical “scavenger”, exerts potent antioxidant effects[36] and contributes to their protection from oxidative injury[37]. In addition, in vitro and in vivo studies have suggested that vitamin E is also able to improve immune-system functions[38], mainly by increasing cell-mediated-immunity[39]. Mechanisms involved in these complex processes remain poorly understood, but, a recent systematic review has summarized its possible intracellular targets and suggested its potential direct antiviral or immunostimulating activities against HBV[40]. Vitamin E is able to influence the transcriptional function of some cellular genes by directly interacting with their promoter sequences[41] and it may modulate the post-transcriptional regulation of protein synthesis[42]. In particular, very preliminary studies have demonstrated that vitamin E is able to regulate the expression profiles of some microRNAs, but it is conceivable that it interacts with a larger number of these molecules[43].
In this trial, the period of supplementation with this dosage used was equal to 100 mg/d for three months, probably not enough to induce an improvement of anti-HBV activity of the immune system by means of a direct anti-viral action both by decreasing its replication abilities and by boosting the host’s immune cell responses. The slow but progressive delay of HBV replication associated with HBeAg loss/HBeAb seroconversion, as described in 2 of the 3 studies included in our meta-analysis, corroborates the hypothesis that vitamin E acts as an immunomodulator resulting in a global antiviral activity. Interestingly, a delayed response has already been reported, with the use of immunomodulatory drugs for the treatment of adults with CHB[58]. In Fiorino’s study, HBeAg seroconversion was also observed in additional 7 of 11 previously non-responder patients in the vitamin E supplemented group, with an extended follow-up for an additional period of 12 mo[20]. This observation underlines the importance of the duration of the treatment period and might contribute to explaining, at least in part, the absence of children responding to vitamin E therapy in Dickici’s study[18]. In this trial, the period of supplementation with this compound was only three months long, in addition the dosage used was equal to 100 mg/d for three months, probably not enough to induce an improvement of antiviral immune responses. Therefore, both dosage and duration of vitamin E supplementation represent very important factors that must be considered when its anti-viral efficacy is evaluated. Taking into considerable account all the described factors, our study seems to suggest that vitamin E use may effectively enhance the probability to induce HBeAg seroconversion in these patients, even in children in the immune-tolerant phase. However, it has to be considered that our meta-analysis has several limits. First, the very small number of available studies enrolling children with HBeAg positivity-related hepatitis, as well as the small size of these trials may increase publication and selection biases; second, one research study has been carried out in Asia[48] and 2 studies in Europe[19,20]; it is not known whether differences in response rates, following vitamin E use, may exist among children belonging to different ethnicities or depending on the different prevalence of HBV genotypes; third, the study design did not include the use of placebo in control groups in two studies[18,20]; fourth, it has to be taken into account that HBeAg seroconversion rate in children in the immunetolerant phase is < 2% among children younger than 3 years and 4%-5% among older children[54] and that data concerning HBV genotypes as well as children’s seroconversion rates by age groups were available only for one of the studies considered for the meta-analysis. Therefore, this limit precludes further proper assessments of the potential vitamin E benefits in children under 14 years as well as of its potential efficacious dose. However, in the study by Fiorino et al[20], patients who responded to vitamin E treatment were respectively 4 (1 child), 13 (2 children), 14 (2 children), and 17 (2 children) years old at the enrollment (Table 1).

In addition, it has to be considered that some meta-analyses[55,61] have reported that long-term administration of vitamin E, at dosages exceeding 150 UI once a day, is associated with serious negative outcomes, such as an increase in all-cause mortality. However, although the conclusions of these studies are rather questionable[57-60]
because of the meta-analytic approaches used and no severe side effects have been described in the three included trials, with the exception of some adverse events, represented by flares of transaminases, these results suggest caution in the generalization of vitamin E administration in the pediatric population before confirmation of the effectiveness and safety of this compound. Certainly, vitamin E, which was administered at high dosage to the children in the reported trials, has to be considered as a drug, with possible benefits as well as with potential risks. Therefore, to date these limiting factors prevent the formulation of definitive recommendations on the role of this type of treatment in children with HBeAg-positive hepatitis. However, to our knowledge this is the first attempt to quantitatively assess the therapeutic effects and efficacy of vitamin E in the treatment of these subjects. These patients suffer from a viral-related liver disease, a condition associated with a deficiency in immune system responses. Therefore, the use of vitamin E in patients with HBV chronic infection might represent an approach combining the direct antiviral effect of nucleoside/nucleotide analogues on HBV replication together with the immune-enhancing role of this fat-soluble compound. Therefore, further well-designed and adequately-sized trials are required to confirm or deny these preliminary, but apparently very interesting and promising, results with the aim to establish the potentially useful dose of vitamin E to induce HBeAg seroconversion.

ACKNOWLEDGMENTS

The authors thank Dr. Simonetta Righi, Biblioteca Centralizzata, Policlinico S Orsola-Malpighi, Università di Bologna, Bologna, Italy for her support in the search of scientific bibliography and Dr. Cecilia Baroncini IRCCS - Institute of Neurological Sciences of Bologna, Italy for her support in the linguistic revision of the manuscript.

REFERENCES

1. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
2. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol 2015; 7: 2127-2132 [PMID: 26328023 DOI: 10.4254/wjh.v7.i11.2127]
3. Bhat M, Ghali P, Deschenes M, Wong P. Prevention and Management of Chronic Hepatitis B. Int J Prev Med 2014; 5: S200-S207 [PMID: 26622990]
4. Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther 2016; 44: 213-222 [PMID: 27302653 DOI: 10.1111/apt.13694]
5. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-1555 [PMID: 26231459 DOI: 10.1016/S0140-6736(15)61412-X]
6. Della Corte C, Nobili V, Comparcola D, Caielli F, Vento S. Management of chronic hepatitis B in children: an unresolved issue. J Gastroenterol Hepatol 2014; 29: 912-919 [PMID: 24863185 DOI: 10.1111/jgh.12550]
7. Pungapong S, Kim WR, Poterucha J. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82: 967-975 [PMID: 17673066 DOI: 10.4065/82.8.967]
8. Defresco F, Sokal E. Chronic hepatitis B virus in children: therapeutic challenges and perspectives. J Gastroenterol Hepatol 2016; 31: 1-9 [PMID: 27262164 DOI: 10.1111/jgh.13459]
9. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg serocconversion. J Viral Hepat 2007; 14: 147-152 [PMID: 17305879 DOI: 10.1111/j.1365-2893.2006.00810.x]
10. Bertolotti G, Guido M, Bartolacci S, Cadrobi P, Crivellaro C, Noventa F, Morsica G, Moriondo M, Gatta A. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-562 [PMID: 16496323 DOI: 10.1002/hep.21077]
11. Wu JF, Chiu YC, Chang KC, Chen HL, Ni YH, Hsu HY, Chang MH. Predictors of hepatitis B e antigen-positive hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood. Hepatology 2016; 63: 74-82 [PMID: 26389515 DOI: 10.1002/hep.28222]
12. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen serocconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995; 22: 1387-1392

COMMENTS

Background

Hepatitis B virus (HBV) chronic infection in childhood continues to represent a very important clinical problem in several countries worldwide and the treatment indications for this subset of patients are still an area of considerable uncertainty. Clear-cut guidelines are lacking, therefore, to date, therapeutic decisions are only based on the consensus of expert panels.

Research frontiers

A protective immune response is considered a crucial factor in maintaining a persistent infection in subjects with HBV. Drugs able to restore an adequate immune activity could contribute to promote an effective control of this infection.

Innovations and breakthroughs

In the real-life clinical setting, a wide proportion of children with persistent HBV infection remain untreated and a conservative approach is generally applied in these subjects. Therefore, the introduction of additional therapies and different strategies in clinical practices required. Since several years ago, vitamin E has emerged as a compound with a large spectrum of immune-stimulatory activities and its use could improve the defective immune activity detectable in several diseases, including chronic viral infections. This research field could be very interesting, but this kind of application requires caution. Some reports, although rather questionable, report possible harmful effects, when this compound is used at high dose.

Applications

Vitamin E administration could represent one among the options for the treatment of children with HBV chronic infection, either as mono-therapy in the developing countries with limited economic resource or, for the future, in combination with standard antiviral drugs. The decrease in viral replication and antigen burden as well as the restoration of an adequate immune function might represent an effective approach for the management of patients with HBV persistent infection.

Peer-review

The authors underwent a meta-analysis to evaluate the role of vitamin E administration to children with immune tolerant HBV infection. Results showed a nearly four-fold likelihood of achieving HBeAg seroconversion in those children receiving vitamin E. Sensitivity analysis showed that exclusion of any of the three studies did not change results.
Fiorino S et al. Vitamin E in pediatric hepatitis B infection

13 Loggi E, Gamal N, Bihl F, Bernardi M, Andreone P. Adaptive response in hepatitis B virus infection. J Viral Hepat 2014; 21: 304-829. DOI: 10.1111/j.1365-3156.2013.01255.

14 Stoop JN, van der Molen BG, Bann CC, van der Laan LJ, Kuipers EJ, Kusters JW, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-778. DOI: 10.1002/hep.20649.

15 Andreone P, Fiorino S, Cursaro C, Gramenzi A, Margotti M, Di Giammarino L, Biselli M, Miniero R, Gasbarrini G, Bernardi M. Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res 2001; 25: 79-81. DOI: 10.1101/s0166-5240(02)00141-8.

16 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012. DOI: 10.1016/j.jclinepi.2009.06.005.

17 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Wirth S, Socha P, Vajro P, Lacaille F, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Urban S, Li W, Wenzl TG, Zense M, Hector A, Dockter G, Adam R, Neubert D, Murray K. Antiviral therapy in management of chronic childhood hepatitis B: results of a randomized phase 2 controlled trial. J Hepatol 2014; 60: 7208-7213. DOI: 10.1016/j.jhep.2014.07.032.

18 Fiorino S, Loggi E, Verucchi G, Comparrada D, Vukotic R, Pavoni M, Grandini E, Cursaro C, Maselli S, BacchiReggiani ML, Puggioli C, Badia L, Galli S, Viale P, Bernardi M, Andreone P. Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. Liver Int 2016; 36: 54-61. DOI: 10.1111/ liver.13192.

19 Gerner P, Posselt HG, Krahl A, Ballaufa C, Innerhofer A, Binder C, Wenzl TG, Zense M, Hector A, Dockter C, Adam R, Neubert D, Murray K, Mathurin P, Flaherty JF, Lin L, Jonas MM. Randomized, placebo-controlled trial of tenofovir diosproxil fumarate in children with chronic hepatitis B: interferon or nucleoside analogues. Liver Int 2016; 36: 2892-2905. DOI: 10.1111/j.1442-200X.2007.02419.x.

20 Jonas MM, Lok AS, McMahon BJ, Brown RS, Wong JB, Ahmed AT, Farah W, Mouchli MA, Singh S, Prokop LJ, Murad MH, Andreone P. Antiviral therapy in management of chronic hepatitis B infection in children: A systematic review and meta-analysis. Hepatology 2016; 63: 307-318. DOI: 10.1002/hep.28278.

21 El Sherbini A, Omar A. Treatment of children with HBeAg-positive chronic hepatitis B: a systematic review and meta-analysis. Dig Liver Dis 2014; 46: 1103-1110. DOI: 10.1016/j.dld.2014.08.032.

22 Sokal EM, Conjevarasm HS, Roberts EA, Alvarez F, Bern EM, Goyes P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995. DOI: 10.1016/S0016-5085(98)70318-X.

23 Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Veggente A, Little NR, Gardener SD, Jonas MM. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006; 43: 225-232. DOI: 10.1002/hep.21020.

24 Jonas MM, Chang MH, Sokal E, Schwarz KB, Kelly D, Kim KM, Ling SC, Rosenthal P, Orasveau D, Reynolds L, Thiry A, Ackerman P. Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology 2016; 63: 377-387. DOI: 10.1002/hep.28015.

25 Jonas MM, Kelly D, Pollack H, Mizerski J, Sorbel J, Frederick D, Mondou E, Rousseau F, Sokal E. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008; 47: 1863-1871. DOI: 10.1002/hep.22250.

26 Murray KF, Zensorn L, Wysocki J, Rossi S, Corica AC, Din H, McHutchinson J, Pang PS, Luminos LM, Pawloska M, Mizerski J. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 1802-1806. DOI: 10.1002/hep.25183.

27 Iorio R, Tufano M, Giagnori MG, Spagnuolo ML, Giannattasio F. What evidence exists to support antiviral treatment in children with chronic hepatitis B? AntivirTher 2014; 19: 225-227. DOI: 10.21926/antivir.2014.0044.

28 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int 2013; 33 Suppl 1: 137-150. DOI: 10.1111/j.1442-200X.2012.06785.x.

29 Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Jonas MM, Aminoglyc, Gagg, Subramanian GM, McChutchion JG, Lao G, Lee S, Gane EJ. Effects of tenofiro disoproxi fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014; 146: 1240-1248. DOI: 10.1002/hep.28015.

30 Watashi K, Urban S, Li W, Wakiita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci 2014; 15: 2892-2905. DOI: 10.3390/ijms15022443.

31 Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic hepatitis B virus infection. World J Gastroenterol 2012; 18: 2443-2451. DOI: 10.3748/wjg.v18.i20.2443.

32 Meydani M. Vitamin E. Lancet 1995; 345: 170-175. DOI: 10.1016/S0140-6736(95)90172-8.

33 Peh HY, Tan WS, Liao W, Wong WS. Vitamin E therapy beyond cancer: Tocopherol versus tocotrienol. Pharmacol Ther 2016; 162: 152-169. DOI: 10.1016/j.pharmthera.2015.12.003.

34 Atkinson J, Harroun T, Wassell SR, Stillwell W, Katsaras J. The location and behavior of alpha-tocopherol in membranes. Mol Nutr Food Res 2010; 54: 641-651. DOI: 10.1002/mnfr.200900439.

35 Wu D, Mura C, Beharka AA, Han SN, Paulson KE, Hwang D, Meydani SN. Age-associated increase in PGE2 synthesis and COX activity in murine macrophages is reversed by vitamin E. Am J Physiol 1998; 275: C661-C668. DOI: 9730949.

36 Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free RadioJ Biol Med 2007; 43: 4-15. DOI: 10.1756/j.freeradiobiomed.2007.03.024.

37 Pallast EG, Schouen EG, de Waart FG, Fonk HC, Doekes G, van Blomberg BM, Kok FJ. Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons. Am J ClinNutr 1999; 69: 1273-1281. DOI: 10.1093/ajcn/69.6.1273.

38 Meydani MN, Han SN, Wu D. Vitamin E and immune response in the aged: molecular mechanisms and clinical implications. Immunol Rev 2005; 205: 269-284. DOI: 10.1111/j.0161-286X.2005.00274.x.

39 Fiorino S, BacchiReggiani L, Sabbatani S, Grizzi F, di Tommaso L, Masetti M, Fornelli A, Bondi A, de Biase D, Visani M, Cuppini A, Stoop JN, van der Molen BG, Bann CC, van der Laan LJ, Kuipers EJ, Kusters JW, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus-related persistent infection: a systematic review. Br J Nutr 2014; 112: 1751-1760. DOI: 10.1017/
Fiorino S et al. Vitamin E in pediatric hepatitis B infection

S0007114514002839

Rimbach G, Moehring J, Huebbe P, Lodge JK. Gene-regulatory activity of alpha-tocopherol. Molecules 2010; 15: 1746-1761 [PMID: 20336011 DOI: 10.3390/molecules15031746]

Tang XL, Xu MJ, Li ZH, Pan Q, Fu JH. Effects of vitamin E on expressions of eight microRNAs in the liver of Nile tilapia (Oreochromis niloticus). Fish Shellfish Immunol 2013; 34: 1470-1475 [PMID: 23542605 DOI: 10.1016/j.fsi.2013.03.353]

Chojkier M, Houglum K, Lee KS, Buck M. Long- and short-term D-alpha-tocopherol supplementation inhibits liver collagen alpha1(1) gene expression. Am J Physiol 1998; 275: G1480-G1485 [PMID: 9843787]

Gaedicke S, Zhang X, Schmelzer C, Lou Y, Doering F, Frank J, Rimbach G. Vitamin E dependent microRNA regulation in rat liver. FEBS Lett 2008; 582: 3542-3546 [PMID: 18817776 DOI: 10.1016/j.febslet.2008.09.032]

Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 2011; 8: 354 [PMID: 21762537 DOI: 10.1186/1743-422X-8-354]

Radhakrishnan AK, Mahalingam D, Selvaduray KR, Nesaretnam K. Supplementation with natural forms of vitamin E augments antigen-specific TH1-type immune response to tetanus toxoid. FEBS Lett 2013; 2013; 582067 [PMID: 23936847 DOI: 10.1155/2013/582067]

Jiang Q, Yin X, Lill MA, Danielsen ML, Freiser H, Huang J. Long-chain carboxychoromicals, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. Proc Natl Acad Sci USA 2008; 105: 20464-20469 [PMID: 19074288 DOI: 10.1073/pnas.0810692206]

Yu Y, Gong R, Mu Y, Chen Y, Zhe C, Sun Z, Chen M, Liu Y, Zhu W, Wu J. Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. J Immunol 2011; 187: 4844-4860 [PMID: 21957142 DOI: 10.4049/jimmunol.1100998]

Raich J, Darfeuille-Michaud A, Nguyen HT. Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol 2013; 19: 2985-2996 [PMID: 23716978 DOI: 10.3748/wjg.v19.i20.2985]

Chen Y, Shen A, Rider PJ, Yu Y, Wu K, Mu Y, Hao Q, Liu Y, Gong H, Zhu Y, Liu F, Wu J. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FEBS J 2011; 25: 4511-4521 [PMID: 21903935 DOI: 10.1066/j.febsl.198781]

Andreone P, Cursaro C, Gramenzi A, Zavagliz C, Rezakovic I, Altomare E, Severini R, Franzone JS, Albano O, Iode G, Bernardi M, Gasbarrini G. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B. Hepatology 1996; 24: 774-777 [PMID: 8855175 DOI: 10.1001/0003-4819-142-1-200501040.110]

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842-857 [PMID: 17327526 DOI: 10.1001/jama.297.238.842]

Gerss J, Köpcke W. The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches. Cell Mol Biol (Noisy-le-grand) 2009; 55 Suppl: OL1111-OL1120 [PMID: 19267994]

Meydani SN, Lah J, Dalal GE, Meydani M. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med 2005; 143: 153; author reply 156-158 [PMID: 16027466 DOI: 10.7326/0003-4819-143-2-200507190.00023]

Krishnan K, Campbell S, Stone WL. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med 2005; 143: 151; author reply 156-158 [PMID: 16027462 DOI: 10.7326/0003-4819-143-2-200507190.00019]

Jialal I, Devaraj S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med 2005; 143: 155; author reply 156-158 [PMID: 16027470 DOI: 10.7326/0003-4819-143-2-200507190.00026]
